Maintenance infliximab does not result in increased abscess development in fistulizing Crohn's disease: results from the ACCENT II study

    loading  Checking for direct PDF access through Ovid


SummaryBackgroundRapid fistula healing may predispose Crohn's disease patients to abscess development.AimData from ACCENT II were analysed to determine whether fistula-related abscess development is affected by infliximab exposure.MethodsFollowing infliximab 5 mg/kg infusions at weeks 0, 2 and 6, patients were evaluated for fistula response for two consecutive visits at least 4 weeks apart. Patients (N = 282) were randomized at week 14 to either placebo or infliximab 5 mg/kg every 8 weeks through week 46. If response was lost at or after week 22, patients could crossover to a 5 mg/kg higher infliximab dose. Fistula-related abscesses were diagnosed by physical examination or by imaging procedures according to usual practice.ResultsInfliximab exposure was approximately twofold higher for the infliximab maintenance group. Twenty-one (15%) patients in the infliximab maintenance group had at least one newly developed fistula-related abscess compared with 27 (19%) in the placebo maintenance group (P = 0.526). The proportion of patients with a new fistula-related abscess was similar regardless of whether or not patients crossed over to a 5 mg/kg higher infliximab dose. The number of fistula-related abscesses diagnosed over time did not differ between groups.ConclusionAbscess development in patients with fistulizing Crohn's disease is not dependent on cumulative infliximab exposure.

    loading  Loading Related Articles